balanced with the seriousness of sudden vision changes, can support informed, confident decision making rather than alarm.
The new class-wide GLP-1 RA labeling changes for potential NAION risk do not signal that these medications are unsafe overall. Instead, they reflect an evolving evidence base and a commitment to making sure patients and professionals have the information needed to respond quickly if rare problems arise. GLP-1 RAs remain key therapies for many individuals with type 2 diabetes and obesity, but they now carry an additional point of vigilance. By recognizing symptoms